Sections
Log in
Top News
U.S. News World News Featured Voices
Odd News
Entertainment
Movies Music TV
Sports
Soccer NFL NBA MLB NHL Golf Horse Racing Tennis Col. Football Col. Basketball
Photos
News Entertainment Sports Features Archives
More...
Defense Featured Science Health Archive Almanac
About Feedback
About Feedback
Search
Trending
9/11 fund
Payless
Theodore McCarrick
Jussie Smollett
Illinois shooting
Iran attack
Laurie Hernandez
'Alexa & Katie'
Nigeria election
Colin Kaepernick
Stephen Curry
YNW Melly
Health News
July 11, 2018 / 12:30 PM

FDA to require stronger warnings for potent group of antibiotics

Antibiotics called fluoroquinolones will now include warnings about potential drops in blood sugar and neurological side effects that can include delirium and memory problems.

By
HealthDay News
The FDA announced that a powerful class of antibiotics called fluoroquinolones, which includes drugs such as Cipro, will now come with stronger warnings about potentially dangerous side effects. Photo by EmilianDanaila/Pixabay

WEDNESDAY, July 11, 2018 -- A powerful class of antibiotics will now come with stronger safety warnings about dangerous drops in blood sugar and neurological side effects that can include delirium and memory problems, the U.S. Food and Drug Administration said Tuesday.

Called fluoroquinolones, these drugs include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin, gemifloxacin (Factive) and delafloxacin (Baxdela). There are more than 60 generic versions of fluoroquinolones.

"The use of fluoroquinolones has a place in the treatment of serious bacterial infections -- such as certain types of bacterial pneumonia -- where the benefits of these drugs outweigh the risks," Dr. Edward Cox, director of the FDA's Office of Antimicrobial Products, said in an agency news release.

What kinds of infections should not be treated with these antibiotics?

RELATED Combining antibiotics alters effectiveness, study says

According to the agency, the risks generally outweigh the benefits of fluoroquinolone treatment for patients with acute sinusitis, acute or chronic bronchitis and uncomplicated urinary tract infections.

Fluoroquinolones already carried warnings about a number of neurological side effects, but those warnings differed by drug.

Fluoroquinolone labels must now list the blood sugar warning and all potential neurological side effects associated with this class of antibiotics -- such as attention problems, disorientation, agitation, nervousness, memory impairment and delirium.

RELATED Fewer antibiotics, more ADHD drugs prescribed for kids

The FDA said the decision to require stronger safety warnings came after a review of reports of side effects it had received, as well as case reports published in medical journals.

Fluoroquinolones also carry warnings about disabling and potentially permanent side effects involving tendons, muscles, joints, nerves and the central nervous system.

More information

Consumer Reports has more on fluoroquinolones.

RELATED Common meds may help spur antibiotic resistance, study finds

Copyright © 2018 HealthDay. All rights reserved.

  • Topics
  • Food and Drug Administration
Follow us on Facebook, Twitter and Instagram for more UPI news and photos.

Trending Stories

Number of push-ups men can do in a row may indicate heart health
HPV unlikely to be spread by hands, researchers say
Study: Chemical in Roundup may increase cancer risk by 40 percent
Hip and knee replacements show high durability, study shows
FDA approves first customizable insulin pump

Photo Gallery

 
Palestinians celebrate Valentine's Day

Latest News

UPI Almanac for Monday, Feb. 18, 2019
Famous birthdays for Feb. 18: Dr. Dre, Toni Morrison
On This Day: Dozens die in Kiev, Ukraine, protests
Fashion icon Lee Radziwill dies at 85
Stephen Curry ends All-Star Game with reverse slam off bounce alley-oop
 
Back to Article
/
Back to top
About UPI Contact Feedback Advertisements Submit News Tips
Copyright © 2019 United Press International, Inc. All Rights Reserved.
Terms of UsePrivacy Policy